Medical News

RSS

Rhei granted marketing approval for MuGard in China

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.

24 Feb 2012

Standard Register fourth quarter revenue decreases to $161.4M

Standard Register today announced its financial results for the fourth quarter and full year 2011. The Company reported revenue of $161.4 million and a net loss of $95.5 million, or $3.28 per diluted share for the fourth quarter of 2011.

24 Feb 2012

More smokers choose vaping over smoking

Many people like the idea of smoking a lot more than they like the reality, and more of them are choosing vaping over smoking every day. Vaping? Well, electronic cigarettes use vapor not smoke, so users don't smoke them.

24 Feb 2012

SANUWAVE, CAN-med Healthcare enter distribution agreement for dermaPACE device

SANUWAVE Health, Inc. has entered into a two-year exclusive distribution agreement with CAN-med Healthcare, a division of IMP Group Limited, to distribute the Company's dermaPACE device throughout Canada.

24 Feb 2012

Depressive symptoms of fathers lead to mental health problems in children

Voluminous research literature attests to the multiple negative consequences of maternal depression and depressive symptoms for the health and development of children. In contrast, there is a profound paucity of information about depressive symptoms in fathers according to a follow up study by NYU School of Medicine researchers in the February 23rd online edition of Maternal and Child Health Journal.

24 Feb 2012

YM BioSciences prices 35,000,000 common shares in underwritten public offering

YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer related products, today announced the pricing of 35,000,000 common shares at US$2.00 per common share in its previously announced underwritten public offering.

24 Feb 2012

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo Pharmaceuticals today reported financial results for the fourth quarter of 2011.

24 Feb 2012

New erectile dysfunction supplement with Bio-Energy infusion

As Neutra Corp. works to finalize the formula for its new Pure Plus erectile dysfunction supplement, the company has already confirmed the new product's most important ingredient: The Bio-Energy infusion that will turbocharge the supplement's effectiveness.

24 Feb 2012

MRI on the nanoscale closer to realty

Magnetic resonance imaging (MRI) on the nanoscale and the ever-elusive quantum computer are among the advancements edging closer toward the realm of possibility, and a new study co-authored by a UC Santa Barbara researcher may give both an extra nudge. The findings appear today in Science Express, an online version of the journal Science.

24 Feb 2012

Cyberonics third quarter net sales increase 16% to $54.5 million

Cyberonics, Inc. today announced results for the quarter ended January 27, 2012.

24 Feb 2012

Blue Belt's Navio PFS System receives CE Mark approval

Blue Belt Technologies, Inc., a medical device company focused on developing the next generation of "smart" surgical instruments providing precise robotic control for use initially in orthopedic procedures and then for other surgical specialties including neurosurgery, spinal and otolaryngology, announced today that it has received CE Mark for the Navio™ PFS System.

24 Feb 2012

First Edition: February 24, 2012

Today's headlines include reports detailing what becomes of the deficit -- particularly at this time of rising Medicare costs for the aging population -- under the plans being advanced by the GOP presidential candidates.

24 Feb 2012

Biofund, Quintiles to expand clinical development services in Russia

Russian Venture Company Biofund, a Russian-based investment firm, and Quintiles, the world's leading biopharmaceutical services company, today announced a definitive agreement to support expansion of clinical development services within the Russian Federation, the world's ninth most populous country.

24 Feb 2012

New Huntington's drug might operate via previously unknown mechanisms of action

A study from Karolinska Institutet in Sweden shows that a new drug for Huntington's disease - pridopidine or dopamine stabiliser ACR16 - might operate via previously unknown mechanisms of action. Researchers have found that at very low concentrations, ACR16 binds to the sigma-1 receptor, a protein in the brain important to neuronal function and survival.

24 Feb 2012

Western Dental Services celebrates expansion into Northern California

Western Dental Services, Inc., celebrates its continuing expansion into Northern California with a ribbon-cutting ceremony on Tuesday, February 28th, at its newest office in Livermore.

24 Feb 2012

Researchers uncover how phytoplankton release powerful toxins into environment

Each year, phytoplankton blooms known as "red tides" kill millions of fish and other marine organisms and blanket vast areas of coastal water around the world. Though the precise causes of red tides remain a mystery, a team of researchers in the United States and Spain has solved one of the main riddles about these ecological disasters by uncovering the specific mechanism that triggers phytoplankton to release their powerful toxins into the environment.

24 Feb 2012